Drugs · acquisition-cost intelligence
sumatriptan
· ingredient sumatriptan· SUMATRIPTAN 20 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$16.06
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other sumatriptan products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Sumatriptan | $0.34058 | −$15.72 |
| Treximet | $11.67 | −$4.39 |
| Sumatriptan | $15.06 | −$1.00 |
| sumatriptan | $17.57 | +$1.51 |
| sumatriptan | $69.54 | +$53.47 |
| IMITREX | $72.50 | +$56.43 |
| Tosymra | $108.15 | +$92.09 |
| Zembrace SymTouch | $384.03 | +$367.96 |
Medicare Part D coverage · CY2026
On 311 plan formularies · typical tier 4
Prior auth 0% · Step therapy 1% · Quantity limit 97% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.